Brokerages Anticipate Infinity Pharmaceuticals Inc. (INFI) Will Announce Earnings of -$0.17 Per Share
Wall Street brokerages forecast that Infinity Pharmaceuticals Inc. (NASDAQ:INFI) will post ($0.17) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have made estimates for Infinity Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.18) and the highest is ($0.16). Infinity Pharmaceuticals reported earnings per share of ($0.14) in the same quarter last year, which indicates a negative year-over-year growth rate of 21.4%. The business is scheduled to announce its next quarterly earnings report on Thursday, March 21st.
On average, analysts expect that Infinity Pharmaceuticals will report full year earnings of ($0.23) per share for the current year, with EPS estimates ranging from ($0.25) to ($0.22). For the next financial year, analysts anticipate that the business will post earnings of ($0.74) per share, with EPS estimates ranging from ($0.79) to ($0.70). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that cover Infinity Pharmaceuticals.
Infinity Pharmaceuticals (NASDAQ:INFI) last posted its earnings results on Monday, November 5th. The biotechnology company reported $0.23 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.14) by $0.37. The firm had revenue of $22.00 million during the quarter.
In related news, major shareholder Bvf Partners L. P/Il bought 91,474 shares of the stock in a transaction dated Thursday, November 15th. The stock was acquired at an average price of $1.35 per share, for a total transaction of $123,489.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Value Fund L. P. Biotechnology bought 100,000 shares of the stock in a transaction dated Wednesday, November 28th. The stock was bought at an average price of $1.30 per share, with a total value of $130,000.00. The disclosure for this purchase can be found here. Over the last 90 days, insiders bought 3,730,634 shares of company stock worth $5,090,055. Company insiders own 11.45% of the company’s stock.
Several hedge funds have recently bought and sold shares of INFI. Acadian Asset Management LLC grew its stake in shares of Infinity Pharmaceuticals by 95.2% in the second quarter. Acadian Asset Management LLC now owns 372,009 shares of the biotechnology company’s stock valued at $711,000 after buying an additional 181,436 shares in the last quarter. Algert Global LLC acquired a new stake in shares of Infinity Pharmaceuticals in the second quarter valued at about $139,000. Dimensional Fund Advisors LP grew its stake in shares of Infinity Pharmaceuticals by 27.0% in the second quarter. Dimensional Fund Advisors LP now owns 932,370 shares of the biotechnology company’s stock valued at $1,781,000 after buying an additional 198,098 shares in the last quarter. Essex Investment Management Co. LLC grew its stake in shares of Infinity Pharmaceuticals by 121.4% in the third quarter. Essex Investment Management Co. LLC now owns 364,401 shares of the biotechnology company’s stock valued at $988,000 after buying an additional 199,796 shares in the last quarter. Finally, Northpointe Capital LLC acquired a new stake in shares of Infinity Pharmaceuticals in the third quarter valued at about $1,433,000. Institutional investors and hedge funds own 52.16% of the company’s stock.
Infinity Pharmaceuticals stock traded down $0.10 during trading hours on Friday, hitting $1.21. The stock had a trading volume of 469,809 shares, compared to its average volume of 855,698. The firm has a market capitalization of $75.63 million, a price-to-earnings ratio of -1.46 and a beta of 2.51. Infinity Pharmaceuticals has a 1-year low of $1.22 and a 1-year high of $2.92.
About Infinity Pharmaceuticals
Infinity Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study.
Further Reading: Earnings Reports
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.